Metabolism of glucagon-like peptide-2 in pigs: Role of dipeptidyl peptidase IV

Regulatory Peptides

Volumn 138, Issue 2-3, 2007, Pages 126-132

  Hansen, Lene ^a   Hare, Kristine J ^a   Hartmann, Bolette ^a   Deacon, Carolyn F ^a   Ugleholdt, Randi K ^a   Plamboeck, Astrid ^a   Holst, Jens J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

DPP IV; GLP 2; MCR; Valine pyrrolidide

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 [3-33]; UNCLASSIFIED DRUG; VALINE PYRROLIDIDE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; EXTRACTION; HORMONE METABOLISM; KIDNEY; LIVER; METABOLIC CLEARANCE RATE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; RADIOIMMUNOASSAY; SPLANCHNIC BLOOD FLOW; SWINE;

ANIMALS; ANTIGENS, CD26; GLUCAGON-LIKE PEPTIDE 2; HALF-LIFE; INFUSIONS, INTRAVENOUS; KIDNEY; METABOLIC CLEARANCE RATE; PYRROLES; SWINE; TISSUE DISTRIBUTION; VALINE;

SUIDAE;

EID: 33846032686     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.08.012     Document Type: Article

References (31)

1. Hartmann B., Thulesen J., Hare K.J., Kissow H., Orskov C., Poulsen S.S., and Holst J.J. Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regul Pept 105 (2002) 173-179
2. Drucker D.J., Erlich P., Asa S.L., and Brubaker P.L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 93 (1996) 7911-7916
3. Jeppesen P.B., Hartmann B., Thulesen J., Graff J., Lohmann J., Hansen B.S., Tofteng F., Poulsen S.S., Madsen J.L., Holst J.J., and Mortensen P.B. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120 (2001) 806-815
4. Jeppesen P.B. Clinical significance of GLP-2 in short-bowel syndrome. J Nutr 133 (2003) 3721-3724
5. Holst J.J. Enteroglucagon. Annu Rev Physiol 59 (1997) 257-271
6. Holst J.J. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18 (2002) 430-441
7. Deacon C.F., Pridal L., Klarskov L., Olesen M., and Holst J.J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271 (1996) E458-E464
8. Deacon C.F., Hughes T.E., and Holst J.J. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47 (1998) 764-769
9. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214 (1993) 829-835
10. Hartmann B., Harr M.B., Jeppesen P.B., Wojdemann M., Deacon C.F., Mortensen P.B., and Holst J.J. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 85 (2000) 2884-2888
11. Hartmann B., Thulesen J., Kissow H., Thulesen S., Orskov C., Ropke C., Poulsen S.S., and Holst J.J. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 141 (2000) 4013-4020
12. Brubaker P.L., Crivici A., Izzo A., Ehrlich P., Tsai C.H., and Drucker D.J. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 138 (1997) 4837-4843
13. Xiao Q., Boushey R.P., Drucker D.J., and Brubaker P.L. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 117 (1999) 99-105
14. Drucker D.J., Shi Q., Crivici A., Sumner-Smith M., Tavares W., Hill M., DeForest L., Cooper S., and Brubaker P.L. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15 (1997) 673-677
15. Munroe D.G., Gupta A.K., Kooshesh F., Vyas T.B., Rizkalla G., Wang H., Demchyshyn L., Yang Z.J., Kamboj R.K., Chen H., McCallum K., Sumner-Smith M., Drucker D.J., and Crivici A. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A 96 (1999) 1569-1573
16. Thulesen J., Knudsen L.B., Hartmann B., Hastrup S., Kissow H., Jeppesen P.B., Orskov C., Holst J.J., and Poulsen S.S. The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept 103 (2002) 9-15
17. Ruiz-Grande C., Pintado J., Alarcon C., Castilla C., Valverde I., and Lopez-Novoa J.M. Renal catabolism of human glucagon-like peptides 1 and 2. Can J Physiol Pharmacol 68 (1990) 1568-1573
18. Tavares W., Drucker D.J., and Brubaker P.L. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 278 (2000) E134-E139
19. Deacon C.F., Danielsen P., Klarskov L., Olesen M., and Holst J.J. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50 (2001) 1588-1597
20. Hartmann B., Johnsen A.H., Orskov C., Adelhorst K., Thim L., and Holst J.J. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 21 (2000) 73-80
21. Wojdemann M., Wettergren A., Hartmann B., and Holst J.J. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 33 (1998) 828-832
22. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85 (1999) 9-24
23. Deacon C.F., Johnsen A.H., and Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80 (1995) 952-957
24. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., and Holst J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44 (1995) 1126-1131
25. Vilsboll T., Agerso H., Krarup T., and Holst J.J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88 (2003) 220-224
26. Lambeir A.M., Proost P., Scharpe S., and De M.I. A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro. Biochem Pharmacol 64 (2002) 1753-1756
27. Lojda Z. Studies on dipeptidyl(amino)peptidase IV (glycyl-proline naphthylamidase). II. Blood vessels. Histochemistry 59 (1979) 153-166
28. Simonsen L., Holst J.J., and Deacon C.F. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 49 (2006) 706-712
29. Hansen L., Hartmann B., Mineo H., and Holst J.J. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept 118 (2004) 11-18
30. Toft-Nielsen M.B., Madsbad S., and Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 (1999) 1137-1143
31. Deacon C.F., Wamberg S., Bie P., Hughes T.E., and Holst J.J. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172 (2002) 355-362